Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001426 · ClinicalTrials.gov registry record · Phase 2
A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT00001426: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00001426 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 66 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001426, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
A supra-additive cytotoxic effect was seen when CAI and paclitaxel were given to human ovarian cancer cells sequentially in tissue culture. We have demonstrated that CAI given for 8 days followed by paclitaxel is reasonably well tolerated and that paclitaxel administration causes a dose-dependent increase in CAI plasma concentration. CAI is a cytostatic drug and continuous exposure is needed. This study will evaluate the combination of continuously administered CAI with three-weekly paclitaxel.
Interventions
- DRUG Cyclophosphamide
- DRUG Cisplatin
- DRUG G-CSF
- DRUG Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 1995-02-03 |
| Est. Completion | 2013-11-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001426
The ClinicalTrials.gov registry entry for NCT00001426 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT00001426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001426 about?
NCT00001426 is a clinical study titled "A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer". A supra-additive cytotoxic effect was seen when CAI and paclitaxel were given to human ovarian cancer cells sequentially in tissue culture. We have demonstrated that CAI given for 8 days followed by paclitaxel is reasonably well tolerated and that paclitaxel administration causes a dose-dependent in...
What is the current status of trial NCT00001426?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 1995-02-03. Estimated completion is 2013-11-07.
What interventions are being tested in trial NCT00001426?
The interventions under investigation include: Cyclophosphamide (DRUG), Cisplatin (DRUG), G-CSF (DRUG), Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00001426?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.